The mission of the Scientific Centre of Drug and Medical Technology Expertise is to implement the national drug policy, to ensure the safety, efficacy and quality of medicinal products in RA. According to the recommendations of the World Health Organization (WHO), The Scientific Centre of Drug and Medical Technology Expertise (SCDMTE) was founded in 1992 as an organization with managerial, financial and technical independence which is accountable to the Ministry of Health of the RA. 

 

THE MAIN ACTIVITIES OF THE CENTRE

  1. Expertise and evaluation. Expert assessment of medicines (including veterinary drugs), herbal drugs, medical cosmetics, dietary supplements, medical devices with the purpose of state registration.

  2. Expertise of import and export. Professional expertise of medicines for certification of their import and export.

  3. Specialized expertise of pharmaceutical organizations for assuring the appropriate quality of medicines and other pharmaceutical products, available at the pharmaceutical market of Armenia, as well as detecting counterfeit drugs.

  4. Control over Narcotics and Psychotropic Substances. Calculation of an annual demand (quota) of narcotics and psychotropic substances in RA, certification of import and export of narcotics and psychotropic substances and submission of reports to UN International Narcotics Control Board.

  5. Monitoring adverse effects of drugs. Registration of adverse drug reactions in the RA and provision of relevant information to the WHO International Program on Monitoring Adverse Drug Reactions (Uppsala, Sweden).

  6. Implementation of the concept of rational use of drugs. Review and update of the National Essential Medicines List, development of optimal schemes of pharmacotherapy, study of drug prescription practice, carrying out the pharmaco-epidemiological researches.

  7. Control of clinical trials. Expertise of protocols and other required documents with the purpose of permition of the clinical trials in RA, as well as monitoring of current clinical trials.

  8. Informational and publishing activity. Publication of contemporary, objective information on pharmacotherapy, medicines and other pharmaceutical products, as well as guide books, manuals and formularies.

  9. Legislative activity. Participation in the development of the legislative documents related to National drug policy and its implementation.

  10. Research activity. Conduction of studies in the field of medicine and pharmacy, surveys of pharmaceutical market, pharmaco-economic analysis. The Centre has functioning Scientific Board.

  11. Educational activity. Organization of educational workshops and seminars, also in cooperation with WHO and other international organizations.

  12. Skill formation and advanced training. Participation in under- and post-graduate educational programs. The Centre is the base for Clinical Pharmacology Department of the National Institute of Health MoH RA.

The Centre employs more than 80 experts of pharmacology, clinical pharmacology, pharmacy, toxicology, chemistry, and biotechnology. They regularly participate in the international conferences and advanced trainings. 

The Centre has a well-equipped laboratory of drug quality control. 

The Centre has observer status in European Pharmacopoeia Commission since 2009. 

The activity of the Centre has been highly evaluated by WHO and other international organizations.

 
Download this file (Structure16eng1.pdf)Download[Organigramm]